Tag - Derek Archila

Markets

Analysts start Prometheus Biosciences at OP and buy

Analysts for Stifel and SVB Leerink initiated coverage of Prometheus Biosciences (NASDAQ:RXDX) with “outperform” and “buy” ratings, respectively, and price targets of $25 and $34, respectively. The stock closed at $19...

April 6, 2021

Markets

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

May 12, 2020

Markets

Stifel cuts DBV Technologies to hold; PT to $6 from $18

Stifel downgraded DBV Technologies (NASDAQ:DBVT) to “hold” from “buy” and slashed its price target to $6 from $18 after the FDA raised questions about DBV’s Viaskin Peanut’s efficacy, including the impact of patch...

March 17, 2020

Markets

Stifel cuts Vanda Pharma to hold; PT to $17 from $26

Stifel downgraded Vanda Pharmaceuticals (NASDAQ:VNDA) to “hold” from “buy” and cut its price target to $17 from $26 after a deeper look into a FDA lawsuit against the company, its pipeline and execution risk. The stock...

July 25, 2019

Feature

Stifel analyst discusses emerging NASH therapeutic space

As a director and senior analyst covering the biotechnology sector at Stifel, Derek Archila combines analytic ability and industry experience. He has held executive positions covering biotechnology and specialty...

July 12, 2019

Tag - Derek Archila

Analysts start Prometheus Biosciences at OP and buy

Analysts upgrade CymaBay Therapeutics and raise PTs

Stifel cuts DBV Technologies to hold; PT to $6 from $18

Stifel cuts Vanda Pharma to hold; PT to $17 from $26

Stifel analyst discusses emerging NASH therapeutic space

General

More